Rituximab Market Segmentation:
Distribution Channel Segment Analysis
The hospital pharmacies segment in the rituximab market is expected to garner the largest revenue during the forecast period. Due to the growing use of rituximab for cancer therapy in hospitals, the hospital pharmacies segment is expected to account for a total market share of 39.7% by 2035. The dominant position of the sector is expected to be achieved during the forecast period by rising healthcare spending around the world, increased awareness levels for patients, and availability of superior hospital infrastructure in high-income countries.
Application Segment Analysis
The blood cancer segment is expected to hold 24% share of the global rituximab market by 2035. Nearly every 3 minutes, one person in the US is diagnosed with blood cancer. Leukaemia was the sixth most frequent cause of cancer deaths in men from 2013 to 2017 and the seventh most frequent cause in women in the US. Also, the increased funding and investment in healthcare mostly in cancer is driving the growth of the market. The cases associated with blood cancer are expected to increase in the upcoming years due to lifestyle factors which will significantly boost the market growth of rituximab.
Our in-depth analysis of the global market includes the following segments:
|
Distribution Channel |
|
|
Application |
|
